Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 24 JANUARY 2024

A&M Activist Alert -January, 2024

Alvarez & Marsal
Explore more from Alvarez & Marsal

Our latest A&M Activist Alert ("AAA") report reviews how successful shareholder activists have been at choosing their targets, and how such activism will evolve in Europe through 2024.

GlobalCorporate/Commercial Law
Alvarez & Marsal
Alvarez & Marsal

Our latest A&M Activist Alert ("AAA") report reviews how successful shareholder activists have been at choosing their targets, and how such activism will evolve in Europe through 2024.

The number of activist campaigns in Europe has increased year-on-year, up to 193 in 2023 compared with 173 in 2022 – an increase of 12%. The pressure on Boards is expected to continue in 2024, with 146 corporates identified as being at heightened risk of a public activist attack.

Click to download the A&M Activist Alert 2024 Outlook

In this year's edition, we delve into six key themes driving the predicted growth in public activist campaigns through 2024 and beyond:

  • All shareholders benefit from increasing activist campaigns creating a financial incentive to hear their constructive challenges.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP